drug manufacturers

CSL Behring is one of the world's largest manufacturers of plasma-derived and recombinant therapies. They are a leading producer of immunoglobulin products used to treat CIDP, PIDD, and other immune-mediated conditions. CSL Behring's portfolio includes several IVIG and subcutaneous immunoglobulin products that are critical for patients with rare diseases.

Grifols is a global healthcare company and one of the largest producers of plasma-derived medicines. Their immunoglobulin products are used to treat primary immunodeficiency, CIDP, and other conditions requiring immunoglobulin replacement or immunomodulation.

Takeda is a global biopharmaceutical company with a strong presence in immunology, gastroenterology, and rare diseases. Their immunology portfolio includes subcutaneous immunoglobulin products and biologics for inflammatory bowel disease. Takeda is also a major producer of plasma-derived therapies.

GC Biopharma (formerly Green Cross) is a South Korean biopharmaceutical company specializing in plasma-derived therapies. Their IVIG product, Alyglo, is indicated for PIDD. GC Biopharma has been expanding its presence in the U.S. market for immunoglobulin products.

Octapharma is a Swiss-based pharmaceutical company and one of the largest manufacturers of human protein products derived from plasma. Their immunoglobulin products include Octagam and Panzyga, used for PIDD, ITP, and other immune-mediated conditions.

ADMA Biologics is a specialty biopharmaceutical company focused on manufacturing, marketing, and developing plasma-derived biologics. Their flagship product Asceniv is a next-generation IVIG product specifically indicated for PIDD, offering standardized antibody levels.

Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, develops treatments across immunology, oncology, and neuroscience. Their immunology portfolio includes Stelara (ustekinumab), Tremfya (guselkumab), and Simponi (golimumab) — major biologics for psoriasis, IBD, and inflammatory arthritis. Janssen also has a strong oncology portfolio.

AbbVie is one of the world's largest biopharmaceutical companies, known for Humira (the best-selling drug in history) and its expanding immunology, oncology, and aesthetics portfolios. AbbVie's immunology portfolio includes treatments for RA, psoriasis, Crohn's disease, UC, and atopic dermatitis.

Regeneron Pharmaceuticals is a biotechnology company known for its innovative therapies in ophthalmology, immunology, and oncology. Dupixent (dupilumab), co-developed with Sanofi, is one of the most prescribed biologics for atopic dermatitis, asthma, and other type 2 inflammatory conditions. Eylea (aflibercept) is a leading anti-VEGF therapy for retinal diseases.

Genentech, a member of the Roche Group, is a pioneering biotechnology company with a major presence in oncology, immunology, and neuroscience. Their portfolio includes Ocrevus (the leading MS therapy), Rituxan (rituximab), and multiple oncology drugs. Genentech has robust patient support programs.

Amgen is one of the world's largest biotechnology companies, with a diverse portfolio spanning oncology, bone health, cardiovascular, and inflammation. Amgen is also a leading biosimilar manufacturer, offering biosimilar versions of several major biologics. Their patient support programs help navigate complex insurance requirements.

Pfizer is one of the world's largest pharmaceutical companies with a broad portfolio including immunology, oncology, rare diseases, and vaccines. Their specialty drugs include Xeljanz (JAK inhibitor), Ibrance (oncology), and several biosimilars. Pfizer has comprehensive patient support and financial assistance programs.

Alexion, now part of AstraZeneca's Rare Disease unit, specializes in treatments for rare and ultra-rare diseases. They are best known for Soliris and Ultomiris, complement inhibitors used to treat myasthenia gravis, PNH, and aHUS. These are among the most expensive drugs in the world, making insurance navigation especially critical.

Bristol-Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, and cardiovascular disease. Their portfolio includes Opdivo (nivolumab), Yervoy (ipilimumab), and Orencia (abatacept). BMS has a strong presence in immuno-oncology and CAR-T therapy.

Novartis is a global pharmaceutical company with a strong presence in immunology, oncology, ophthalmology, and gene therapy. Their immunology portfolio includes Cosentyx (secukinumab) and their rare disease unit offers transformative gene therapies. Novartis also has a growing biosimilar portfolio through Sandoz (now independent).